Amy Abernethy, former No. 2 at FDA, outlines new company’s plans to streamline clinical research
Oct. 17, 2024
FDA Reporter
Former Verily executive Amy Abernethy outlined her plan to streamline clinical research on Thursday, revealing the first projects that her company, Highlander Health, will fund.
Abernethy, who previously served as the No. 2 official at the Food and Drug Administration, has spent a lot of time thinking about how to leverage data to improve our health, telling STAT in September that the idea for Highlander Health dates back to 2009.
advertisement
Her resolve to make research more efficient has grown over the years as the cost of clinical trials has skyrocketed. On Thursday, at the 2024 STAT Summit, Abernethy recalled a presentation at last year’s J.P. Morgan by BeiGene CEO John Oyler, who noted that the company spent about $150,000 per clinical trial patient in 2010. By 2023, that cost increased to around $300,000 per patient.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 months Get StartedThen $399/year
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe Log In research, STAT Summit Submit a correction requestReprints
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
